Please login to the form below

Not currently logged in
Email:
Password:

eye disorders

This page shows the latest eye disorders news and features for those working in and with pharma, biotech and healthcare.

Virtual reality

Virtual reality

Other groups are using VR applications to provide motor and cognitive training to stroke and multiple sclerosis patients, treat headache, correct eye disorders such as strabismus and help people cope with

Latest news

  • Bayer and Regeneron to develop second wet AMD therapy Bayer and Regeneron to develop second wet AMD therapy

    The partners already market Eylea (aflibercept) for use in a number of eye disorders, including wet AMD, and now want to develop a complementary therapy that can be used in combination ... The companies are banking on the two drugs complementing each

  • NICE backs two eye treatments NICE backs two eye treatments

    NICE backs two eye treatments. Novartis’ Lucentis and Alimera’ s Iluvien received green light for NHS use. ... The National Institute for Heath and Care Excellence (NICE) today recommended two treatments for eye disorders for use on the NHS in

  • ReNeuron wins orphan status for stem cell therapy ReNeuron wins orphan status for stem cell therapy

    ReNeuron wins orphan status for stem cell therapy. ReN003 is being assessed as a treatment for rare eye disorder retinitis pigmentosa. ... of inherited eye disorders that affect the retina and can cause severe impairment to vision.

  • Lucentis cleared in Europe for pathological myopia Lucentis cleared in Europe for pathological myopia

    Pathological myopia affects 1 to 3 per cent of the world's population, in some patients leads to the growth of abnormal leaky blood vessels in the back of the eye ... in visual acuity after just two injections into the affected eye.

  • FDA approves Alcon eye drug Simbrinza FDA approves Alcon eye drug Simbrinza

    FDA approves Alcon eye drug Simbrinza. Fixed-combination licensed to treat glaucoma patients in the US. ... Novartis subsidiary Alcon has been given a boost after US regulators approved its fixed-combination eye treatment Simbrinza Suspension.

More from news
Approximately 5 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics